CPSE:AMBU B

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Ambu A/S develops, manufactures, and sells medical devices to hospitals, clinics, and rescue services worldwide. More Details


Snowflake Analysis

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has Ambu's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AMBU B is not significantly more volatile than the rest of Danish stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: AMBU B's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

-2.6%

AMBU B

4.1%

DK Medical Equipment

1.3%

DK Market


1 Year Return

114.6%

AMBU B

23.0%

DK Medical Equipment

26.9%

DK Market

Return vs Industry: AMBU B exceeded the Danish Medical Equipment industry which returned 19% over the past year.

Return vs Market: AMBU B exceeded the Danish Market which returned 23.7% over the past year.


Shareholder returns

AMBU BIndustryMarket
7 Day-2.6%4.1%1.3%
30 Day-1.9%1.5%3.2%
90 Day25.5%4.8%13.1%
1 Year114.9%114.6%24.4%23.0%29.3%26.9%
3 Year91.1%89.7%81.8%75.3%56.1%43.9%
5 Year484.9%475.2%135.9%116.9%68.0%46.4%

Long-Term Price Volatility Vs. Market

How volatile is Ambu's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Ambu undervalued compared to its fair value and its price relative to the market?

8.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AMBU B (DKK248.5) is trading below our estimate of fair value (DKK272.82)

Significantly Below Fair Value: AMBU B is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: AMBU B is poor value based on its PE Ratio (254.2x) compared to the DK Medical Equipment industry average (70.7x).

PE vs Market: AMBU B is poor value based on its PE Ratio (254.2x) compared to the Danish market (17.5x).


Price to Earnings Growth Ratio

PEG Ratio: AMBU B is poor value based on its PEG Ratio (7.7x)


Price to Book Ratio

PB vs Industry: AMBU B is overvalued based on its PB Ratio (26x) compared to the DK Medical Equipment industry average (10.3x).


Next Steps

Future Growth

How is Ambu forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

33.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AMBU B's forecast earnings growth (33.1% per year) is above the savings rate (0.2%).

Earnings vs Market: AMBU B's earnings (33.1% per year) are forecast to grow faster than the Danish market (12.5% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: AMBU B's revenue (17.5% per year) is forecast to grow faster than the Danish market (6.6% per year).

High Growth Revenue: AMBU B's revenue (17.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AMBU B's Return on Equity is forecast to be high in 3 years time (25.5%)


Next Steps

Past Performance

How has Ambu performed over the past 5 years?

8.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AMBU B has high quality earnings.

Growing Profit Margin: AMBU B's current net profit margins (6.8%) are lower than last year (11.2%).


Past Earnings Growth Analysis

Earnings Trend: AMBU B's earnings have grown by 8% per year over the past 5 years.

Accelerating Growth: AMBU B's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: AMBU B had negative earnings growth (-23.9%) over the past year, making it difficult to compare to the Medical Equipment industry average (-23.9%).


Return on Equity

High ROE: AMBU B's Return on Equity (10.2%) is considered low.


Next Steps

Financial Health

How is Ambu's financial position?


Financial Position Analysis

Short Term Liabilities: AMBU B's short term assets (DKK1.2B) exceed its short term liabilities (DKK1.0B).

Long Term Liabilities: AMBU B's short term assets (DKK1.2B) do not cover its long term liabilities (DKK1.5B).


Debt to Equity History and Analysis

Debt Level: AMBU B's debt to equity ratio (53%) is considered high.

Reducing Debt: AMBU B's debt to equity ratio has reduced from 76.1% to 53% over the past 5 years.

Debt Coverage: AMBU B's debt is well covered by operating cash flow (23.5%).

Interest Coverage: AMBU B's interest payments on its debt are well covered by EBIT (15.3x coverage).


Balance Sheet


Next Steps

Dividend

What is Ambu current dividend yield, its reliability and sustainability?

0.12%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: AMBU B's dividend (0.12%) isn’t notable compared to the bottom 25% of dividend payers in the Danish market (0.95%).

High Dividend: AMBU B's dividend (0.12%) is low compared to the top 25% of dividend payers in the Danish market (3.39%).


Stability and Growth of Payments

Stable Dividend: AMBU B is not paying a notable dividend for the Danish market, therefore no need to check if payments are stable.

Growing Dividend: AMBU B is not paying a notable dividend for the Danish market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: AMBU B is not paying a notable dividend for the Danish market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AMBU B's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.9yrs

Average management tenure


CEO

Juan Gonzalez (48 yo)

1.67yrs

Tenure

kr.24,000,000

Compensation

Mr. Juan Jose Gonzalez has been Chief Executive Officer of Ambu A/S since May 15, 2019 and also had been its President since 2019 until 2019. He serves as Member of Executive Board at Ambu A/S. He is Direc...


CEO Compensation Analysis

Compensation vs Market: Juan's total compensation ($USD3.91M) is about average for companies of similar size in the Danish market ($USD3.57M).

Compensation vs Earnings: Juan's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Juan Gonzalez
CEO & Member of Executive Board1.67yrskr.24.00m0.065%
DKK 38.8m
Michael Hojgaard
CFO, Executive VP of Global Finance8yrskr.7.90m0.0075%
DKK 4.4m
Thomas Henriksen
Head of HR Systems & Employee Representative Director4yrskr.300.00k0.0040%
DKK 2.4m
Jakob Kristensen
Senior Director of Anaesthesia8yrskr.300.00k0.0028%
DKK 1.7m
Jakob Koch
Head of IP & Employee Representative Director4yrskr.300.00k0.0012%
DKK 693.0k
Henrik Ankjær
Executive Vice President of Global Operations2.25yrsno datano data
Nicolai Thomsen
IR Managerno datano datano data
Anders Williamsson
Managing Directorno datano datano data
Måns Barsne
Executive Vice President of Global Innovation & Chief Innovation Officer6yrsno datano data
Steven Block
CEO & President of USA7.75yrsno datano data
Chresten Christensen
Director General of Ambu S.R.L. & Ambu S.L.no datano datano data
Keith McCallum
Managing Director of Ambu UK19.83yrsno datano data

6.9yrs

Average Tenure

48yo

Average Age

Experienced Management: AMBU B's management team is seasoned and experienced (6.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Thomas Henriksen
Head of HR Systems & Employee Representative Director4yrskr.300.00k0.0040%
DKK 2.4m
Jakob Kristensen
Senior Director of Anaesthesia8yrskr.300.00k0.0028%
DKK 1.7m
Jakob Koch
Head of IP & Employee Representative Director4yrskr.300.00k0.0012%
DKK 693.0k
Christian Sagild
Independent Vice-Chairman of the Board1yrkr.450.00k0.10%
DKK 60.9m
Mikael Worning
Independent Vice Chairmanno datakr.700.00k0.027%
DKK 16.0m
Henrik Wulff
Independent Director5.08yrskr.400.00k0.0043%
DKK 2.5m
Britt Jensen
Director1.08yrskr.315.00k0.0016%
DKK 953.6k
Jorgen Jensen
Chairman of the Board1yrno datano data

4.0yrs

Average Tenure

49yo

Average Age

Experienced Board: AMBU B's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Ambu A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ambu A/S
  • Ticker: AMBU B
  • Exchange: CPSE
  • Founded: 1937
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr.59.232b
  • Shares outstanding: 247.94m
  • Website: https://www.ambu.com

Number of Employees


Location

  • Ambu A/S
  • Baltorpbakken 13
  • Ballerup
  • Capital Region of Denmark
  • 2750
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AMBU BCPSE (OMX Nordic Exchange Copenhagen)YesClass B SharesDKDKKAug 1992
AMBF.FOTCPK (Pink Sheets LLC)YesClass B SharesUSUSDAug 1992
AMBUBCBATS-CHIXE (BATS 'Chi-X Europe')YesClass B SharesGBDKKAug 1992
0MJFLSE (London Stock Exchange)YesClass B SharesGBDKKAug 1992
AMBU NBMV (Bolsa Mexicana de Valores)YesClass B SharesMXMXNAug 1992
AMBB.YOTCPK (Pink Sheets LLC)UNSPONSORD ADRUSUSDJul 2017

Biography

Ambu A/S develops, manufactures, and sells medical devices to hospitals, clinics, and rescue services worldwide. It provides healthcare solutions in the fields of visualization, anesthesia, and patient mon...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/25 18:05
End of Day Share Price2021/01/25 00:00
Earnings2020/09/30
Annual Earnings2020/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.